Safety and Effectiveness of CD4-IgG2 in HIV-Positive Children
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
CD4-IgG2 is a special man-made protein that was built to block the entrance of HIV into CD4
cells (cells of the immune system that fight infection). The purpose of this study is to see
if giving CD4-IgG2 to HIV-infected children is safe and effective.
HIV attaches to CD4 cells and enters them. Inside, HIV makes copies of itself that will help
the virus invade the body. CD4 cells are killed or disabled during this process of HIV
replication. Decreases in CD4 cells lead to a weakened immune system. When CD4 cell counts
become very low, the body is unable to defend itself, and HIV infection develops into AIDS.
The protein used in this study, CD4-IgG2, may be able to attach to HIV and inactivate it so
that it cannot enter CD4 cells. This is an early study to examine CD4-IgG2 as a possible
treatment for HIV in children.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)